Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CNRMF's PB Ratio is ranked better than 75.81% of 1228
companies
in the Biotechnology industry
Industry Median: 2.905
vs CNRMF: 1.42
During the past 12 months, China Regenerative Medicine International's average Book Value Per Share Growth Rate was 112.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -21.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -19.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -48.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of China Regenerative Medicine International was 54.80% per year. The lowest was -78.80% per year. And the median was -0.85% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
China Regenerative Medicine International PB Ratio Related Terms
China Regenerative Medicine International PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International PB Ratio Chart
China Regenerative Medicine International Annual Data
For the Biotechnology subindustry, China Regenerative Medicine International's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Regenerative Medicine International PB Ratio vs Biotechnology Industry
China Regenerative Medicine International PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
China Regenerative Medicine International (CNRMF) has a PB Ratio of 1.52 as of Aug. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Regenerative Medicine International and its competitors. This is 38% below median its historical median of 2.46. Over the past decade, China Regenerative Medicine International's PB Ratio has ranged from 0.25 to 27.94. According to the industry distribution chart, China Regenerative Medicine International ranks #297 out of 1228 companies in the Biotechnology industry, placing it in the top 24.2%.
Is China Regenerative Medicine International's PB Ratio too high?
China Regenerative Medicine International's current PB Ratio of 1.52 is 38% below median its 10-year median of 2.46. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 27.94. The Biotechnology industry median PB Ratio is 2.91. China Regenerative Medicine International's value of 1.52 is 47.7% below this industry median. Based on the distribution chart, China Regenerative Medicine International ranks #297 out of 1228 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, China Regenerative Medicine International has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, China Regenerative Medicine International ranks #297 out of 1228 companies for PB Ratio. This places China Regenerative Medicine International in the top 24% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.91. China Regenerative Medicine International's value of 1.52 is 47.7% below this benchmark. Historically, China Regenerative Medicine International's own PB Ratio has ranged from 0.25 to 27.94 over the past decade. While the company's 10-year median is 2.46 vs. the industry median of 2.91, China Regenerative Medicine International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.91, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Regenerative Medicine International's current PB Ratio of 1.52 is 47.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Regenerative Medicine International and its competitors. For the Biotechnology industry, the median PB Ratio is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Regenerative Medicine International's current PB Ratio is 1.52, which is 38% below median its own 10-year median of 2.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
China Regenerative Medicine International (CNRMF) has a current PB Ratio of 1.52. The stock's GF Value™ is $0.09, compared to a current price of $0.04 — trading 61.1% below its estimated fair value. The current PB Ratio is 1.52, which is 38% below median its 10-year median of 2.46 and 47.7% below the Biotechnology industry median of 2.91. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For China Regenerative Medicine International (CNRMF), the current PB Ratio is 1.52 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Regenerative Medicine International (CNRMF) Overvalued in 2026?
Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued.
The current stock price of $0.04 is trading 61.1% below its estimated GF Value™ of $0.09.
Key valuation signals for CNRMF:
PB Ratio: 1.52 (38% below median its 10-year median of 2.46)
GF Value™: $0.09 vs. price of $0.04 (61.1% below fair value)
Industry Position: 47.7% below the Biotechnology median (#297 of 1228)
No single metric tells the full story. See the CNRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score
Get the complete analysis for CNRMF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNRMF has been successfully added to your 
